Contents
Key Takeaways
- A partnership between Novo Nordisk and Hims & Hers to distribute weight-loss medications together will be unveiled as early as Monday
- Shares of Hims climbed 39% during after-hours trading after the announcement
- The partnership resolves an ongoing legal battle, including a recent patent infringement case initiated by Novo
- Novo had previously cancelled an initial partnership with Hims due to concerns about promotional strategies and compounded medication offerings
- The FDA had previously warned Hims regarding potential enforcement action concerning its $49 compounded semaglutide product
Novo Nordisk and Hims & Hers are joining forces to distribute obesity medications via Hims’ telehealth platform, bringing an end to a contentious legal dispute that had recently intensified into patent litigation.
Bloomberg News broke the story on Friday afternoon, citing sources with knowledge of the agreement. Following the report, Hims stock experienced a dramatic 39% surge in extended trading hours.
An official announcement from both companies is anticipated as early as Monday. The financial details of the partnership arrangement have not been made public.
A Dramatic Shift From Litigation to Collaboration
The reversal is remarkable. Only weeks ago, Novo initiated patent infringement proceedings against Hims following the telehealth firm’s brief introduction of a $49 compounded version of Novo’s weight-loss medication.
The U.S. Food and Drug Administration had simultaneously signaled potential enforcement measures against Hims concerning its compounded semaglutide sales, the same active component found in Wegovy and Ozempic.
Facing both regulatory scrutiny and legal action from Novo, Hims found itself in an increasingly challenging position entering this week.
This marks the second attempt at partnership between these companies. Novo terminated their initial collaboration last year, expressing dissatisfaction with Hims’ promotional approaches and its ongoing distribution of generic Wegovy alternatives.
The newly announced partnership represents a fresh start for both parties, seemingly structured on mutually acceptable terms.
Strategic Implications for Each Company
For Novo, this collaboration provides an additional avenue for distributing its branded obesity treatments amid intensifying competition in the weight-loss pharmaceutical sector.
A Novo representative stated the company is “always in conversation with companies that can help improve patient access to FDA-approved medicines.” The company has offered limited additional public commentary.
Hims declined to provide a statement when contacted for this story.
For Hims, the arrangement represents a strategic shift. The company had previously emphasized compounded semaglutide as an affordable alternative to Novo’s proprietary medications.
This approach became untenable when the FDA removed semaglutide from its shortage list earlier this year, eliminating the regulatory justification for compounding pharmacies to continue manufacturing it.
Current Market Status
Hims stock rallied 39% in after-hours trading on Friday. During the regular trading session, both NVO and HIMS closed lower — NVO declined 1.25% while HIMS dropped 0.88%.
The official partnership announcement is expected as early as Monday, March 9.
